Biohaven Ltd BHVN

NYS: BHVN | ISIN: VGG111961055   26/04/2024
38,97 USD (+1,12%)
(+1,12%)   26/04/2024

22 april 2024 · Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares · Persbericht

18 april 2024 · Biohaven Announces Pricing of $230 Million Public Offering of Common Shares · Persbericht

17 april 2024 · Biohaven Announces Proposed Public Offering of Common Shares · Persbericht

13 april 2024 · Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates · Persbericht

29 februari 2024 · Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments · Persbericht

8 januari 2024 · Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology · Persbericht

2 januari 2024 · Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

1 december 2023 · Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting · Persbericht

16 oktober 2023 · Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® · Persbericht

5 oktober 2023 · Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares · Persbericht

3 oktober 2023 · Biohaven Announces Pricing of $225 Million Public Offering of Common Shares · Persbericht

2 oktober 2023 · Biohaven Announces Proposed Public Offering Of Common Shares · Persbericht

14 september 2023 · Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy · Persbericht

5 september 2023 · Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies · Persbericht

31 juli 2023 · Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy · Persbericht

31 juli 2023 · Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments · Persbericht

27 juli 2023 · Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates · Persbericht

31 mei 2023 · Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day · Persbericht

25 mei 2023 · Biohaven to Present R&D Day at Yale School of Management · Persbericht

12 mei 2023 · Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments · Persbericht

Mijn selecties